Lichen Planus - Pipeline Insight, 2019

"Lichen Planus - Pipeline Insight, 2019" report by outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Lichen Planus pipeline landscape is provided which includes the disease overview and Lichen Planus treatment guidelines. The assessment part of the report embraces, in depth Lichen Planus commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Lichen Planus collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Lichen Planus Understanding
Lichen Planus (LP) is a chronic, immunologically mediated mucocutaneous disease that can affect mucosal surfaces including those that line the oral cavity. It may affect the skin (cutaneous lichen planus), oral cavity (oral lichen planus), genitalia (penile or vulvar lichen planus), scalp (lichen planopilaris), nails, or esophagus. Oral lichen planus may be present in several forms, appearing alone or in combination, namely as Reticular, Atrophic/erosive and Plaque like oral lichen planus. According to the Canadian Dental Association, Reticular oral lichen planus form is the most common among all the other three forms. The majority of patients with oral lesions also have cutaneous lesions and the presence of these characteristics can aid in the diagnosis of OLP. The symptoms of Lichen Planus may begin abruptly or gradually, and the initial attack may persist for weeks or months. The primary spots are 2 to 4 mm in diameter with angular borders (a violet color and a distinct sheen in cross-lighting). According to the American Academy of Oral Medicine, females are predominantly more affected with Lichen Planus than males.
Lichen Planus Pipeline Development Activities
The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Lichen Planus targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Lichen Planus pipeline report covers 8+ companies. Some of the key players include AFYX Therapeutics (Clobetasol Propionate), Celgene (Apremilast), Intas Pharmaceuticals (Nanosomal tacrolimus) etc.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.
Lichen Planus Analytical Perspective by Report
• In-depth Lichen Planus Commercial Assessment of products
This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition –Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.
• Lichen Planus Clinical Assessment of products
The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.
Scope of the report
• The Lichen Planus report provides an overview of therapeutic pipeline activity for Lichen Planus across the complete product development cycle including all clinical and non-clinical stages
• It comprises of detailed profiles of Lichen Planus therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details
• Detailed Lichen Planus Research and Development progress and trial details, results wherever available, are also included in the pipeline study
• Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type
• Coverage of dormant and discontinued pipeline projects along with the reasons if available across Lichen Planus
Reasons to Buy
• Establish a comprehensive understanding of the current pipeline scenario across Lichen Planus to formulate effective R&D strategies
• Assess challenges and opportunities that influence Lichen Planus R&D
• Develop strategic initiatives by understanding the focus areas of leading companies.
• Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Get in detail information of each product with updated information on each project along with key milestones
• Devise Lichen Planus in licensing and out licensing strategies by identifying prospective partners with progressing projects for Lichen Planus to enhance and expand business potential and scope
• Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs